PCI Biotech and RXi Pharmaceuticals extend preclinical research collaboration

PCI Biotech and RXi Pharmaceuticals announced that they are extending their preclinical research collaboration initiated on April 7, 2015. The preclinical research collaboration will evaluate technology compatibility and synergy based on in vivo studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.

PCI Biotech CEO, Per Walday said that he is very pleased to announce the extension of the existing research agreement. Their collaboration with RXi has been most fruitful and demonstrated a clear positive technological synergy that could realize significant value when applied to the emerging field of immuno-oncology. They look forward to exploring synergies between fimaNAc and RXi’s innovative RNAi-based compounds in the extended collaboration focusing on immuno-oncology opportunities.

RXi Pharmaceuticals president and CEO, Geert Cauwenbergh said that their collaboration with PCI Biotech over the last two years has been mutually very beneficial for their companies. They will learn how the PCI technology can even further enhance the time and the concentration their sd-rxRNA compounds can reside and be active in the immune cells. In the immuno-oncology space, where everybody talks about potency and safety of combinations, this continued and more focused collaboration could advance this therapeutic area significantly.